Netupitant

Stathis M, et al. European Journal of Pharmacology, 2012, 689, 25-30.

This case study evaluates the experimental application of Netupitant as a selective NK1 receptor antagonist in cellular signaling assays. Using NG108-15 neuroblastoma × glioma hybrid cells, substance P (SP)-induced intracellular Ca²⁺ mobilization was quantified following antagonist preincubation. Cells were exposed to varying concentrations of Netupitant alone or in combination with palonosetron prior to SP stimulation. Calcium responses were measured to assess receptor-mediated signaling. Netupitant dose-dependently inhibited SP-induced Ca²⁺ mobilization, consistent with NK1 antagonism. Notably, co-application of Netupitant with palonosetron produced enhanced inhibition compared to either agent alone, indicating a synergistic effect. Additional experiments employed selective NK1, NK2, and NK3 agonists to confirm receptor specificity. This experimental design demonstrates Netupitant's utility in dissecting neurokinin receptor signaling and highlights its enhanced functional efficacy when combined with agents that modulate receptor crosstalk.

Ruzza C, et al. Peptides, 2015, 69, 26-32.

This case study focuses on Netupitant as the active pharmacological entity generated from its intravenously suitable prodrug, Pronetupitant, across multiple experimental models. In vitro NK1 antagonism was assessed using receptor binding assays and calcium mobilization studies in CHO cells expressing human NK1 receptors, where inhibition of SP-induced Ca²⁺ influx was quantified after antagonist preincubation. Ex vivo validation employed guinea pig ileum bioassays measuring SP-induced contractile responses. In vivo efficacy was evaluated in mice using the substance P-induced scratching, biting, and licking (SBL) nociception model following intravenous dosing. Pharmacokinetic studies in rats confirmed rapid and complete conversion of Pronetupitant to Netupitant. Collectively, these experimental approaches establish Netupitant as the pharmacodynamically relevant NK1 antagonist in vivo and validate its robust application across cellular, tissue, and animal models.